Notably, combining anti-PD-1 therapy with either a genetic IL-4 KO in tumor cells or with an FDA-approved IL4R-blocking antibody in a clinically relevant OvCa mouse model delayed tumor progression underscoring the translational potential of this strategy as a therapeutic approach (Fig. 1c). The gene discussed is IL4R; the disease is neoplasm.